Fig. 5
From: Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Experimental validation of TCT4U predictions. a The waterfall plot summarizes the results of 14 in vivo experiments comprising 5 PDXs treated with the alpelisib (BYL719) isoform-selective PI3K inhibitor (PI3Ki), 2 PDXs treated with ribociclib (LEE011) CDK4/6 inhibitor (CDKi), 3 PDXs treated with the combination of both (PI3Ki + CDKi), 2 PDXs treated with binimetinib MEK inhibitor (MEKi), and 2 PDXs treated with paclitaxel. The heatmap below shows the predictions based on TCT4U compared to previously known biomarkers. b–e Exemplary tumor response curves and features in the DCO network explaining TCT4U predictions. The size of the nodes represents the average feature importance in the LOOCV. The color of the nodes represents the contribution of each feature to the prediction of response in the given tumor (SHAP values). Previously known biomarkers detected in a given tumor are annotated with diamond shapes. The complete results of our study are provided in Additional file 1: Table S5